Xcovery   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: West Palm Beach FL United States (2005)

Organization Overview

First Clinical Trial
2012
NCT01625234
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Xcovery Holding Company, LLC | Xcovery Holdings, INC

Active Ingredients

Drugs in Phase 3 Trials (2)

crizotinib (xalkori) (1 trial)

x-396 (4 trials)

Drugs in Phase 2 Trials (6)

atezolizumab (Tecentriq) (1 trial)

bpi-361175 (1 trial)

durvalumab (imfinzi) (1 trial)

ensartinib (2 trials)

nivolumab (opdivo) (2 trials)

x-82 (3 trials)

Drugs in Phase 1 Trials (1)

pembrolizumab (keytruda) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 1)

Carcinoma, Hepatocellular (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Lung Neoplasms (Phase 3)

Melanoma (Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Thoracic Neoplasms (Phase 2)

Thymoma (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 9